Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| EyePoint, Inc.EYPT · business equipment | |
|---|---|
| Grade |  Eweakest fifth of 497 graded peers; percentile 92.7, sampling error 2.2 points; lower is stronger |
| Rank | 461 of 497 |
| Profitability | Epercentile 88.9 |
| Solvency | Cpercentile 57.3 |
| Growth and financing | C/Dpercentile 60.6 |
| Reliability | 0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| Peer failure rate | 1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $120M to $591M assetstotal assets $364.0M[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | short runway · fortress balance sheet |
| Inputs computable | 7 of 14 |
| Graded from | filings received through Mar 5, 2026218 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $3.472026-10-08; market equity $299.2M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 5, 2026; the document on sec.gov.
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology (Durasert E™) for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™1, is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with the Company's bioerodible Durasert E™ drug delivery technology.
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 88.9 | |||||||
| Gross profitability | not computable | 28.5% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 10.9% | |||||
| a prior annual debt, equity, and cash observation is required | |||||||
| Accruals ratio | 2.1% | [1,6-8] | (7.4%) | 88.9 | 621 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.4 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 57.3 | |||||||
| Twelve-month failure probability | 0.67% | 0.05% | 92.0 | 101 | 2026-06-30 | ||
| Altman Z double-prime | (3.58) | [1,9-14] | 2.18 | 71.5 | 566 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.11x | |||||
| EBITDA must exceed $100,000 | |||||||
| Interest coverage | not computable | 3.77x | |||||
| latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 | |||||||
| Current ratio | 8.88x | [9-10] | 2.02x | 8.4 | 666 | 2025-12-31 | |
| Growth and financing, sleeve percentile 60.6 | |||||||
| Revenue growth, three-year compound | (8.8%) | [2,15-17] | 6.4% | 85.5 | 538 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 17.2% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 14.3% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Asset growth, three years | 26.4% | [1,8,18-19] | 5.0% | 11.2 | 563 | 2025-12-31 | |
| Net share issuance, one year | 21.4% | [20-21] | 0.5% | 85.0 | 407 | 2026-02-27 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.449; sampling error 2.2 percentile points on 497 peers.
Among 497 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 456 | Hewlett Packard Enterprise Co. (HPE) Hewlett Packard Enterprise Co. (HPE) Eweakest fifth; percentile 91.8 NYSE · Computer & office Equipment last close $70.99 No active warnings; 7 of 14 inputs | 91.8 | E | |
| 457 | Hewlett Packard Enterprise Co. (HPE-PC) Hewlett Packard Enterprise Co. (HPE-PC) Eweakest fifth; percentile 91.8 NYSE · Computer & office Equipment No active warnings; 7 of 14 inputs | 91.8 | E | |
| 458 | Atomera Inc. (ATOM) Atomera Inc. (ATOM) Eweakest fifth; percentile 92.1 Nasdaq · Semiconductors & Related Devices market equity $161.2M; last close $4.13 Warnings: dilution, degenerate inputs; 8 of 14 inputs | 92.1 | E | dilution, degenerate inputs |
| 459 | RideNow Group, Inc. (RDNW) RideNow Group, Inc. (RDNW) Eweakest fifth; percentile 92.3 Nasdaq · Services-Computer Programming Services market equity $10.5M; last close $4.80 No active warnings; 8 of 14 inputs | 92.3 | E | |
| 460 | Quantum Corp. (QMCO) Quantum Corp. (QMCO) Eweakest fifth; percentile 92.5 Nasdaq · Computer Storage Devices market equity $1.1B; last close $29.15 Warnings: dilution, late filer; 7 of 14 inputs | 92.5 | E | dilution, late filer |
| 461 | EyePoint, Inc. (EYPT) EyePoint, Inc. (EYPT) Eweakest fifth; percentile 92.7 Nasdaq · Laboratory Analytical Instruments market equity $298.3M; last close $3.47 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | 92.7 | E | short runway, fortress balance sheet |
| 462 | Bridgeline Digital, Inc. (BLIN) Bridgeline Digital, Inc. (BLIN) Eweakest fifth; percentile 92.9 Nasdaq · Services-Prepackaged Software market equity $9.5M; last close $0.78 Warnings: fortress balance sheet; 9 of 14 inputs | 92.9 | E | fortress balance sheet |
| 463 | Upland Software, Inc. (UPLD) Upland Software, Inc. (UPLD) Eweakest fifth; percentile 93.1 Nasdaq · Services-Prepackaged Software market equity $10.5M; last close $3.55 No active warnings; 9 of 14 inputs | 93.1 | E | |
| 464 | Inseego Corp. (INSG) Inseego Corp. (INSG) Eweakest fifth; percentile 93.3 Nasdaq · Communications Equipment, NEC market equity $73.2M; last close $4.46 Warnings: short runway; 9 of 14 inputs | 93.3 | E | short runway |
| 465 | 3D Systems Corp. (DDD) 3D Systems Corp. (DDD) Eweakest fifth; percentile 93.5 NYSE · Services-Prepackaged Software market equity $556.6M; last close $3.34 Warnings: late filer; 8 of 14 inputs | 93.5 | E | late filer |
| 466 | Professional Diversity Network, Inc. (IPDN) Professional Diversity Network, Inc. (IPDN) Eweakest fifth; percentile 93.8 Nasdaq · Services-Computer Programming, Data Processing, Etc. market equity $2.0M; last close $4.29 Warnings: dilution, short runway; 8 of 14 inputs | 93.8 | E | dilution, short runway |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | E | 93.6 | 2204 |
| sector peers, equal sleeves (the grade) | E | 92.7 | 497 |
| same exchange, equal sleeves | E | 90.6 | 1219 |
| sector peers, equal inputs | E | 84.7 | 497 |
Each letter is one fifth of the 497 graded peers, about 99 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (68.4%) | 2.2% | 6 | hotter than 6 of 100 peers |
| Distance from 52-week high | (81.6%) | (30.0%) | 7 | closer to its high than 7 of 100 peers |
| EBIT to enterprise value | (111.8%) | 1.5% | 4 | pricier than 96 of 100 peers |
| Free cash flow yield | (81.6%) | 2.7% | 4 | pricier than 96 of 100 peers |
| Book value to price | 0.56 | 0.23 | 76 | pricier than 24 of 100 peers |
| Sales to price | 0.11 | 0.30 | 21 | pricier than 79 of 100 peers |
| Composite equity issuance, five years | 109.8% | 3.9% | 93 | more equity-funded than 93 of 100 peers |
| Relative strength against the sector, log excess return | (1.43) | (0.26) | 6 | ahead of 6 of 100 peers |
Inputs: market equity $298.3M; EBIT -$243.4M; free cash flow -$243.4M; book equity $166.4M; sales $31.4M; debt $30.0M; cash $110.5M[22].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (55.4%) | ✗ fail[6,8] |
| Operating cash flow above zero | -$240.1M | ✗ fail[7] |
| Return on assets improved | (18.6 pts) | ✗ fail[6,8,18,23] |
| Operating cash flow exceeds net income | -$8.1M | ✗ fail[6-7] |
| Long-term leverage fell | n/a[1,8,18] | |
| Current ratio improved | 106.2 pts | ✓ pass[9-10,24-25] |
| No new shares issued | 21.4% | ✗ fail[20-21] |
| Gross margin improved | n/a | |
| Asset turnover improved | (4.7 pts) | ✗ fail[2,8,15,18] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $110.5M[3] |
| Operating cash flow, four quarters | -$267.3M[3,7,26-29] |
| Months of runway | 5.0 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 65 |
| 10-Q received Aug 5, 2026 | |
| Median daily dollar volume | $17.3M |
| 63 sessions | |
| Days since newest grade input | 218 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $364.0M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $31.4M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $110.5M | 2026-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
| 4 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $95.6M | 2022-12-31 | 2024-03-08 | 10-K | filing · viewer · series |
| 5 | total debt | us-gaap:LongTermDebt | $30.0M | 2022-12-31 | 2023-03-10 | 10-K | filing · viewer · series |
| 6 | net income | us-gaap:NetIncomeLoss | -$232.0M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 7 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$240.1M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 8 | assets | us-gaap:Assets | $418.5M | 2024-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 9 | current assets | us-gaap:AssetsCurrent | $328.7M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 10 | current liabilities | us-gaap:LiabilitiesCurrent | $37.0M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 11 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.1B | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 12 | operating income | us-gaap:OperatingIncomeLoss | -$243.4M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 13 | book equity | us-gaap:StockholdersEquity | $306.1M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 14 | liabilities | us-gaap:Liabilities | $57.9M | 2025-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $43.3M | 2024-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $46.0M | 2023-12-31 | 2025-03-06 | 10-K | filing · viewer · series |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $41.4M | 2022-12-31 | 2024-03-08 | 10-K | filing · viewer · series |
| 18 | assets | us-gaap:Assets | $355.2M | 2023-12-31 | 2025-03-06 | 10-K | filing · viewer · series |
| 19 | assets | us-gaap:Assets | $180.4M | 2022-12-31 | 2024-03-08 | 10-K | filing · viewer · series |
| 20 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 83,431,950 | 2026-02-27 | 2026-03-05 | 10-K | filing · viewer · series |
| 21 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 68,728,760 | 2025-02-28 | 2025-03-06 | 10-K | filing · viewer · series |
| 22 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 86,212,138 | 2026-07-31 | 2026-08-05 | 10-Q | filing · viewer · series |
| 23 | net income | us-gaap:NetIncomeLoss | -$130.9M | 2024-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 24 | current assets | us-gaap:AssetsCurrent | $383.3M | 2024-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $49.0M | 2024-12-31 | 2026-03-05 | 10-K | filing · viewer · series |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$142.9M | 2026-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$80.5M | 2026-03-31 | 2026-05-07 | 10-Q | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$175.1M | 2025-09-30 | 2025-11-06 | 10-Q | filing · viewer · series |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$115.7M | 2025-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 92.7 is 12.7 points from the nearest band edge; sampling error is 2.2 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
